Merck earnings release, August 4, 2026
- 1 -
Merck & Co., Inc., Rahway, N.J., USA Announces
Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Sales Growth Reflects Continued Strength in
Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR
Financial Highlights
Pipeline & Portfolio Highlights
Full-Year 2026 Financial Outlook¹
Available in some markets as KEYTRUDA SC.
-²
-
RAHWAY, N.J., Aug. 4, 2026 – Merck & Co., Inc., Rahway, N.J.,
USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2026.
“We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches,” said Robert M.
Davis, chairman and chief executive officer. “The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease. Together with key regulatory and clinical advances across oncology, HIV and immunology, this achievement reflects the strength of our pipeline and portfolio transformation as we bring forward the next wave of innovation. I am confident in the ongoing execution of our strategy as we deliver for patients and further enhance our long-term growth trajectory.”
Financial Summary
*Refer to table on page 7.
N/M - Not meaningful
For the second quarter of 2026, Generally Accepted
Accounting Principles (GAAP) loss / earnings per share (EPS) assuming dilution was a loss per share of $0.54 and non-GAAP loss per share was $0.13.
Both the GAAP and non-GAAP loss per share were due to a charge for the acquisition of
Terns
Pharmaceuticals, Inc. (
Terns) of $2.31 per share.
Both GAAP and non-GAAP
EPS in the second quarter of 2025 include a charge of $0.07 per share for an upfront payment related to a license agreement with Jiangsu
Hengrui Pharmaceutical Co., Ltd. (Hengrui Pharma).
Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to restructuring programs, as well as income and losses from investments in equity securities. Non-GAAP EPS in the second quarter of 2025 also excludes tax benefits primarily resulting from favorable audit reserve adjustments.
Year-to-date results can be found in the attached tables.²
Net (loss) income attributable to the Company.³
The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.
-³
-
Second-Quarter Sales Performance
The following table reflects sales of the Company’s top products and significant performance drivers.
-⁴
-
*Alliance revenue for this product represents the
Company’s share of profits, which are product sales net of cost of sales and commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities.
-⁵
-
Second-Quarter Expense and Related Information
The table below presents selected expense information.
GAAP Expense, EPS and Related Information
Gross margin was 73.5% for the second quarter of
2026 compared with 77.5% for the second quarter of 2025.
The decrease was primarily due to higher amortization of intangible assets and inventory write-downs.
Selling, general and administrative (SG&A) expenses were $2.9 billion in the second quarter of 2026, an increase of 10% compared with the second quarter of 2025.
The increase was primarily due to higher administrative costs (including investments in IT), as well as higher promotional costs in support of product launches.
Research and development (R&D) expenses were
$9.7 billion in the second quarter of 2026 compared with $4.0 billion in the second quarter of 2025. The increase was largely due to a
$5.7 billion charge for the acquisition of Terns and higher clinical development spending, partially offset by a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone Life Sciences (Blackstone). R&D expenses in the second quarter of 2025 include a $200 million charge for an upfront payment related to a license agreement with Hengrui Pharma.
Other (income) expense, net, was $99 million of expense in the second quarter of 2026 compared with $7 million of income in the second quarter of 2025.
The unfavorability was primarily due to higher net interest expense, partially offset by higher net income from investments in equity securities.⁴
Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also includes integration,... (truncated) as amortization of intangible assets related to collaborations, licensing arrangements and asset acquisitions, and recognition of fair value step-up to inventories for asset acquisitions.
-⁶
-
The income tax provision for the second quarter of 2026 was
$654 million on a pretax loss of $683 million, resulting in an effective income tax rate of (95.9)%.
This effective income tax rate includes a 108.9 percentage point unfavorable impact of the charge for the acquisition of Terns, for which no tax benefit was recorded.
GAAP loss per share was $0.54 for the second quarter of 2026 compared with earnings per share of $1.76 for the second quarter of 2025, largely due to higher charges for business development transactions, reflecting a $2.31 per share charge in the second quarter of 2026 for the acquisition of Terns compared with a $0.07 per share charge in the second quarter of 2025 related to a license agreement with Hengrui Pharma.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 81.1% for the second quarter of 2026 compared with 82.2% for the second quarter of 2025.
The decrease was primarily due to higher inventory write-downs.
Non-GAAP SG&A expenses were $2.9 billion in the second quarter of 2026, an increase of 10% compared with the second quarter of 2025.
The increase was primarily due to higher administrative costs (including investments in IT), as well as higher promotional costs in support of product launches.
Non-GAAP R&D expenses were $9.7 billion in the second quarter of 2026 compared with $4.0 billion in the second quarter of 2025. The increase was largely due to a $5.7 billion charge for the acquisition of Terns and higher clinical development spending, partially offset by a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone. R&D expenses in the second quarter of 2025 include a $200 million charge for an upfront payment related to a license agreement with Hengrui Pharma.
Non-GAAP other (income) expense, net, was $290 million of expense in the second quarter of 2026 compared with $54 million of expense in the second quarter of 2025.
The unfavorability was primarily due to higher net interest expense.
The non-GAAP income tax provision for the second quarter of 2026 was
$882 million on pretax income of $550 million, resulting in a non-GAAP effective income tax rate of 160.3%. This effective income tax rate includes a 146.2 percentage point unfavorable impact of the charge for the acquisition of Terns, for which no tax benefit was recorded.
Non-GAAP loss per share was $0.13 for the second quarter of 2026 compared with earnings per share of $2.13 for the second quarter of 2025, largely due to higher charges for business development transactions, reflecting a $2.31 per share charge in the second quarter of 2026 for the acquisition of Terns compared with a $0.07 per share charge in the second quarter of 2025 related to a license agreement with Hengrui Pharma.
-⁷
-
A reconciliation of GAAP to non-GAAP net (loss) income and EPS is provided in the table that follows.
Pipeline and Portfolio Highlights
In the second quarter, the Company achieved key regulatory milestones across the portfolio while continuing to advance its broad and diverse pipeline.⁵
Includes the estimated income tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments for all periods presented. Amount in the second quarter of
2025 also includes a $146 million benefit primarily resulting from favorable audit reserve adjustments.
-⁸
-
-⁹
-
-¹⁰
-
Notable recent news releases on the Company’s pipeline and portfolio are provided in the table that follows. Visit the News Releases section of the Company’s website to read the releases.*
*References in the above news release titles have been modified for the purpose of this announcement.
-¹¹
-
Upcoming Investor Event
The Company will hold an Oncology Investor Event to coincide with the European Society for Medical Oncology Congress 2026 on Monday, Oct. 26, 2026, at 6 p.m. CET / 1 p.m. EDT, during which senior management will provide an update on the Company’s oncology strategy and program. The event will take place in Madrid,
Spain, and will be accessible via live audio webcast at this weblink.
Full-Year 2026 Financial Outlook
The following table summarizes the Company’s full-year financial outlook.
*The Company does not have any non-GAAP adjustments to sales.
**Includes one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. (Cidara) and $5.7 billion for the acquisition of Terns. Outlook does not assume any additional significant potential business development transactions.
***Includes one-time charges of $3.62 per share for the acquisition of Cidara and $2.31 per share for the acquisition of Terns.
The Company has not provided a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective income tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot predict with reasonable certainty the amounts necessary for such a reconciliation, including intangible asset impairment charges, legal settlements, and income and losses from investments in equity securities either owned directly or through ownership interests in investment funds, without unreasonable effort. These items are inherently difficult to forecast and could have a significant impact on the Company’s future GAAP results.
The Company is raising and narrowing the range for its full-year sales outlook and now anticipates full-year 2026 sales to be between $66.3 billion and $67.3 billion, including a positive... (truncated)ange of approximately 1% at mid-July 2026 exchange rates.
The Company now expects the full-year non-GAAP effective income tax rate to be between 35.0% and 36.0%, including the impact of the non-tax deductible one-time charges for the acquisitions of Cidara and Terns.
The Company now expects full-year 2026 non-GAAP
EPS to be between $2.66 and $2.76, including a positive impact from foreign exchange of approximately $0.15 per share at mid-July 2026 exchange rates. This range includes one-time charges of $9.0 billion, or $3.62 per share, related to the acquisition of Cidara and $5.7 billion, or $2.31 per share, related to the acquisition of Terns. This range also includes costs of approximately $0.12 per share to finance the Terns acquisition and advance MK-4208. The charges related to Terns were not previously included in the outlook. In 2025, non-GAAP
EPS of $8.98 was negatively impacted by one-time charges of $0.20 per share in the aggregate related to certain business development transactions.
-¹²
-
Consistent with past practice, the financial outlook does not assume additional significant potential business development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call on Tuesday, Aug. 4, at 9 a.m.
EDT via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available on the Company’s website.
All participants may join the call by dialing (800)
369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.
About Our Company
At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J.,
USA
This news release of Merck & Co., Inc., Rahway,
Financial statements
Income Statement
Table 1a (in millions)
| 2026 – 1Q | 2026 – 2Q | 2026 – June YTD | 2025 – 1Q | 2025 – 2Q | 2025 – June YTD | 2025 – 3Q | 2025 – 4Q | 2025 – Full Year | % Change – 2Q | % Change – Full Year | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16,286 | 16,607 | 32,893 | 15,529 | 15,806 | 31,335 | 17,276 | 16,400 | 65,011 | 5.0% | 5.0% | |
| Costs, Expenses and Other | Cost of sales | 4,195 | 4,395 | 8,590 | 3,419 | 3,557 | 6,976 | 3,855 | 5,551 | 16,382 | 24.0% | 23.0% |
| Costs, Expenses and Other | Selling, general and administrative | 2,700 | 2,904 | 5,604 | 2,552 | 2,649 | 5,202 | 2,633 | 2,898 | 10,733 | 10.0% | 8.0% |
| Costs, Expenses and Other | Research and development | 12,592 | 9,741 | 22,333 | 3,621 | 4,048 | 7,669 | 4,234 | 3,886 | 15,789 | ||
| Costs, Expenses and Other | Restructuring costs | 195 | 151 | 346 | 69 | 560 | 629 | 47 | 213 | 889 | -73.0% | -45.0% |
| Costs, Expenses and Other | Other (income) expense, net | 138 | 99 | 237 | -35 | -7 | -43 | -238 | 432 | 151 | ||
| Costs, Expenses and Other | (Loss) Income Before Taxes | -3,534 | -683 | -4,217 | 5,903 | 4,999 | 10,902 | 6,745 | 3,420 | 21,067 | ||
| Costs, Expenses and Other | Income Tax Provision | 709 | 654 | 1,363 | 818 | 571 | 1,388 | 958 | 458 | 2,804 | ||
| Costs, Expenses and Other | Net (Loss) Income | -4,243 | -1,337 | -5,580 | 5,085 | 4,428 | 9,514 | 5,787 | 2,962 | 18,263 | ||
| Costs, Expenses and Other | Less: Net (Loss) Income Attributable to Noncontrolling Interests | -3 | -2 | -5 | 6 | 1 | 8 | 2 | -1 | 9 | ||
| Costs, Expenses and Other | Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | -4,240 | -1,335 | -5,575 | 5,079 | 4,427 | 9,506 | 5,785 | 2,963 | 18,254 | ||
| Costs, Expenses and Other | (Loss) Earnings per Common Share Assuming Dilution (1) | -1.72 | -0.54 | -2.26 | 2.01 | 1.76 | 3.77 | 2.32 | 1.19 | 7.28 | ||
| Costs, Expenses and Other | Average Shares Outstanding Assuming Dilution (1) | 2,472 | 2,470 | 2,471 | 2,531 | 2,513 | 2,522 | 2,498 | 2,488 | 2,507 | ||
| Costs, Expenses and Other | Tax Rate | -20.1% | -95.9% | -32.3 | 13.9% | 11.4% | 12.7% | 14.2% | 13.4% | 13.3 |
Income Statement
Table 2b (in millions)
| GAAP | Acquisition- and Divestiture-Related Costs (1) | Restructuring Costs (2) | (Income) Loss from Investments in Equity Securities | Certain Other Items | Adjustment Subtotal | Non-GAAP | ||
|---|---|---|---|---|---|---|---|---|
| Second Quarter | Cost of sales | 3,557 | 576 | 165 | 741 | 2,816 | ||
| Second Quarter | Selling, general and administrative | 2,649 | 15 | 1 | 16 | 2,633 | ||
| Second Quarter | Research and development | 4,048 | 3 | 53 | 56 | 3,992 | ||
| Second Quarter | Restructuring costs | 560 | 560 | 560 | ||||
| Second Quarter | Other (income) expense, net | -7 | -61 | -61 | 54 | |||
| Second Quarter | Income Before Taxes | 4,999 | -594 | -779 | 61 | -1,312 | 6,311 | |
| Second Quarter | Income Tax Provision (Benefit) | 571 | -3 | -3 | -3 | -146 | -373 | 944 |
| Second Quarter | Net Income | 4,428 | -492 | -640 | 47 | 146 | -939 | 5,367 |
| Second Quarter | Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | 4,427 | -492 | -640 | 47 | 146 | -939 | 5,366 |
| Second Quarter | Earnings per Common Share Assuming Dilution | 1.76 | -0.2 | -0.25 | 0.02 | 0.06 | -0.37 | 2.13 |
| Second Quarter | Tax Rate | 11.4% | 15 | |||||
| June YTD | Cost of sales | 6,976 | 1,196 | 201 | 1,397 | 5,579 | ||
| June YTD | Selling, general and administrative | 5,202 | 38 | 1 | 39 | 5,163 | ||
| June YTD | Research and development | 7,669 | 10 | 53 | 63 | 7,606 | ||
| June YTD | Restructuring costs | 629 | 629 | 629 | ||||
| June YTD | Other (income) expense, net | -43 | -3 | -168 | -171 | 128 | ||
| June YTD | Income Before Taxes | 10,902 | -1,241 | -884 | 168 | -1,957 | 12,859 | |
| June YTD | Income Tax Provision (Benefit) | 1,388 | -3 | -3 | -3 | -146 | -486 | 1,874 |
| June YTD | Net Income | 9,514 | -1,022 | -727 | 132 | 146 | -1,471 | 10,985 |
| June YTD | Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | 9,506 | -1,022 | -727 | 132 | 146 | -1,471 | 10,977 |
| June YTD | Earnings per Common Share Assuming Dilution | 3.77 | -0.4 | -0.29 | 0.05 | 0.06 | -0.58 | 4.35 |
| June YTD | Tax Rate | 12.7% | 14.6 |
Income Statement
Acquisition- and Divestiture- Related Costs4 — The table below presents selected expense information. (in millions)
| Second Quarter 2026 – GAAP | Second Quarter 2026 – Acquisition- and Divestiture- Related Costs4 | Second Quarter 2026 – Restructuring Costs | Second Quarter 2026 – (Income) Loss From Investments in Equity Securities | Second Quarter 2026 – Non- GAAP3 | ||
|---|---|---|---|---|---|---|
| Cost of sales | 4,395 | 1,067 | 184 | 3,144 | ||
| Selling, general and administrative | 2,904 | 17 | 2,887 | |||
| Research and development | 9,741 | 6 | -1 | 9,736 | ||
| Restructuring costs | 151 | 151 | ||||
| Other (income) expense, net | 99 | -191 | 290 | |||
| Second Quarter 2025 | Cost of sales | 3,557 | 576 | 165 | 2,816 | |
| Second Quarter 2025 | Selling, general and administrative | 2,649 | 15 | 1 | 2,633 | |
| Second Quarter 2025 | Research and development | 4,048 | 3 | 53 | 3,992 | |
| Second Quarter 2025 | Restructuring costs | 560 | 560 | |||
| Second Quarter 2025 | Other (income) expense, net | -7 | -61 | 54 |
Income Statement
Second Quarter — A reconciliation of GAAP to non-GAAP net (loss) income and EPS is provided in the table that follows. (in millions)
| Second Quarter – 2026 | Second Quarter – 2025 | ||
|---|---|---|---|
| EPS | GAAP EPS | -0.54 | 1.76 |
| EPS | Difference | 0.41 | 0.37 |
| EPS | Non-GAAP EPS that excludes items listed below3 | -0.13 | 2.13 |
| Net (Loss) Income | GAAP net (loss) income2 | -1,335 | 4,427 |
| Net (Loss) Income | Difference | 1,005 | 939 |
| Net (Loss) Income | Non-GAAP net (loss) income that excludes items listed below2,3 | -330 | 5,366 |
| Excluded Items: | Acquisition- and divestiture-related costs4 | 1,090 | 594 |
| Excluded Items: | Restructuring costs | 334 | 779 |
| Excluded Items: | Income from investments in equity securities | -191 | -61 |
Income Statement
Table 1 (in millions)
| GAAP – 2Q26 | GAAP – 2Q25 | % Change | GAAP – June YTD 2026 | GAAP – June YTD 2025 | % Change | ||
|---|---|---|---|---|---|---|---|
| Sales | 16,607 | 15,806 | 5.0% | 32,893 | 31,335 | 5.0% | |
| Costs, Expenses and Other | Cost of sales | 4,395 | 3,557 | 24.0% | 8,590 | 6,976 | 23.0% |
| Costs, Expenses and Other | Selling, general and administrative | 2,904 | 2,649 | 10.0% | 5,604 | 5,202 | 8.0% |
| Costs, Expenses and Other | Research and development | 9,741 | 4,048 | 22,333 | 7,669 | ||
| Costs, Expenses and Other | Restructuring costs | 151 | 560 | -73.0% | 346 | 629 | -45.0% |
| Costs, Expenses and Other | Other (income) expense, net | 99 | -7 | 237 | -43 | ||
| Costs, Expenses and Other | (Loss) Income Before Taxes | -683 | 4,999 | -4,217 | 10,902 | ||
| Costs, Expenses and Other | Income Tax Provision | 654 | 571 | 1,363 | 1,388 | ||
| Costs, Expenses and Other | Net (Loss) Income | -1,337 | 4,428 | -5,580 | 9,514 | ||
| Costs, Expenses and Other | Less: Net (Loss) Income Attributable to Noncontrolling Interests | -2 | 1 | -5 | 8 | ||
| Costs, Expenses and Other | Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | -1,335 | 4,427 | -5,575 | 9,506 | ||
| Costs, Expenses and Other | (Loss) Earnings per Common Share Assuming Dilution (1) | -0.54 | 1.76 | -2.26 | 3.77 | ||
| Costs, Expenses and Other | Average Shares Outstanding Assuming Dilution (1) | 2,470 | 2,513 | 2,471 | 2,522 | ||
| Costs, Expenses and Other | Tax Rate | -95.9% | 11.4% | -32.3% | 12.7% |
Income Statement
Acquisition- and Divestiture-Related Costs (1) — Table 2a
| Second Quarter – GAAP | Second Quarter – Acquisition- and Divestiture-Related Costs (1) | Second Quarter | Second Quarter – Restructuring Costs (2) | Second Quarter | Second Quarter – (Income) Loss from Investments in Equity Securities | Second Quarter | Second Quarter – Adjustment Subtotal | Second Quarter – Non-GAAP | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of sales | 4,395 | 1,067 | 184 | 1,251 | 3,144 | |||||
| Selling, general and administrative | 2,904 | 17 | 17 | 2,887 | ||||||
| Research and development | 9,741 | 6 | -1 | ) | 5 | 9,736 | ||||
| Restructuring costs | 151 | 151 | 151 | |||||||
| Other (income) expense, net | 99 | -191 | ) | -191 | 290 | |||||
| Loss Before Taxes | -683 | -1,090 | ) | -334 | ) | 191 | -1,233 | 550 | ||
| Income Tax Provision (Benefit) | 654 | -219 | -3 | -50 | -3 | 41 | -3 | -228 | 882 | |
| Net Loss | -1,337 | -871 | ) | -284 | ) | 150 | -1,005 | -332 | ||
| Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA | -1,335 | -871 | ) | -284 | ) | 150 | -1,005 | -330 | ||
| Loss per Common Share Assuming Dilution (4) | -0.54 | -0.35 | ) | -0.12 | ) | 0.06 | -0.41 | -0.13 | ||
| Tax Rate | -95.9 | 160.3 | ||||||||
| June YTD | Cost of sales | 8,590 | 2,081 | 421 | 2,502 | 6,088 | ||||
| June YTD | Selling, general and administrative | 5,604 | 49 | 49 | 5,555 | |||||
| June YTD | Research and development | 22,333 | 6 | 33 | 39 | 22,294 | ||||
| June YTD | Restructuring costs | 346 | 346 | 346 | ||||||
| June YTD | Other (income) expense, net | 237 | -371 | ) | -371 | 608 | ||||
| June YTD | Loss Before Taxes | -4,217 | -2,136 | ) | -800 | ) | 371 | -2,565 | -1,652 | |
| June YTD | Income Tax Provision (Benefit) | 1,363 | -421 | -3 | -135 | -3 | 80 | -3 | -476 | 1,839 |
| June YTD | Net Loss | -5,580 | -1,715 | ) | -665 | ) | 291 | -2,089 | -3,491 | |
| June YTD | Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA | -5,575 | -1,715 | ) | -665 | ) | 291 | -2,089 | -3,486 | |
| June YTD | Loss per Common Share Assuming Dilution (4) | -2.26 | -0.7 | ) | -0.27 | ) | 0.12 | -0.85 | -1.41 | |
| June YTD | Tax Rate | -32.3 | -111.3 |
Full release
N.J., USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful.
If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
-¹³
-
The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site ( www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION
(sugammadex)
CAPVAXIVE
(Pneumococcal 21-valent Conjugate Vaccine)
ENFLONSIA
(clesrovimab-cfor)
GARDASIL
(
Human Papillomavirus Quadrivalent [Types 6,
11, 16 and 18] Vaccine, Recombinant)
GARDASIL 9
(Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET
(sitagliptin and metformin HCl)
JANUVIA
(sitagliptin)
KEYTRUDA
(pembrolizumab)
KEYTRUDA QLEX
(pembrolizumab and berahyaluronidase alfa-pmph)
LAGEVRIO
(molnupiravir)
Lenvima
(lenvatinib)
LIPFENDRA
(enlicitide)
Lynparza
(olaparib)
M-M-R II
(Measles, Mumps and Rubella Virus Vaccine Live)
OHTUVAYRE
(ensifentrine)
PREVYMIS
( letermovir)
PROQUAD
(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
VARIVAX
(Varicella Virus Vaccine Live)
VAXNEUVANCE
(Pneumococcal 15-valent Conjugate Vaccine)
WELIREG
( belzutifan)
WINREVAIR
(sotatercept-csrk)
-¹⁴
-
Animal Health
BRAVECTO
(fluralaner)
###
MERCK & CO., INC., RAHWAY, N.J., USA